In Being Patient’s LiveTalk series, Dr. David Weidman, associate medical director for research at the Banner Alzheimer’s Institute, shares insights on Eli Lilly’s investigational Alzheimer’s…
A recent study suggests that sargramostim, a drug used for patients undergoing chemotherapy as well as bone marrow and blood stem cell transplants, may…
Following the FDA’s approval of the new Alzheimer’s drug Aduhelm (aducanumab), retired neurologist Daniel Gibbs spoke with Being Patient in a recent LiveTalk about…
In light of last week’s long-awaited FDA decision on experimental Alzheimer’s treatment aducanumab, a panel of clinical trials experts looks at why Alzheimer’s drug…
Looking for answers about Alzheimer’s treatment Aduhelm (generic name aducanumab)? Here’s a primer on what it is, what it does, and more, according to…
Following the FDA’s approval of aducanumab, marketed under the name Aduhelm, an aducanumab trial principal investigator and a former aducanumab trial site investigator speak…
The FDA is expected to decide whether or not to approve Biogen and Eisai’s experimental Alzheimer’s drug, aducanumab, in less than a week. Geri…